Bemcentinib As Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy: A Phase Ib/IIa Trial

Scientists reported bemcentinib monotherapy and bemcentinib+low-dose cytarabine combination therapy arms from the completed BerGenBio-funded open-label Phase I/IIb trial in patients unsuitable for intensive chemotherapy.